13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001595855
Total reported value
$1.1B
$1.1B
43 檔
35.7%
The Q3 2025 SEC filing reveals that Opaleye Management Inc. held a total portfolio value of $1.1B, covering 43 public equity positions.
Opaleye Management Inc. executed strategic sector rebalancing during Q3 2025, establishing 14 new positions while fully exiting 16 holdings and trimming 10 positions.
In terms of portfolio concentration, the top 5 core holdings (including HROW, ETON, LQDA) accounted for 35.7% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | HROW | Harrow Inc | Stock-Other | 26.60% | -3.92% | — | |
| 2 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 8.79% | +0.08% | — | |
| 3 | LQDA | Liquidia CORP | Stock-Other | 8.41% | +5.97% | +5.66% | |
| 4 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 6.59% | -3.42% | -2.80% | |
| 5 | IMNM | Immunome Inc | Stock-Other | 5.27% | — | -9.76% | |
| 6 | SNWV | Sanuwave Health Inc | Stock-Other | 5.19% | -1.95% | — | |
| 7 | CDXS | Codexis Inc | Stock-Other | 4.41% | -0.07% | +1.55% | |
| 8 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 2.73% | +0.32% | — | |
| 9 | OCUL | Ocular Therapeutix Inc | Stock-Other | 2.64% | -0.14% | — | |
| 10 | CGON | Cg Oncology Inc | Stock-Other | 2.33% | -0.74% | +54.14% | |
| 11 | STOK | Stoke Therapeutics Inc | Stock-Other | 2.27% | -0.93% | +21.33% | |
| 12 | APGE | Apogee Therapeutics Inc | Stock-Other | 2.04% | +0.37% | — | |
| 13 | ALKS | Alkermes plc | Stock-Healthcare | 1.91% | — | — | |
| 14 | IRON | Disc Medicine Inc | Stock-Other | 1.81% | +2.11% | +3.95% | |
| 15 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.59% | — | +17.00% | |
| 16 | LRMR | Larimar Therapeutics Inc | Stock-Other | 1.49% | — | -9.47% | |
| 17 | XOMA | Xoma Royalty Corporation | Stock-Other | 1.39% | +0.06% | — | |
| 18 | RZLT | Rezolute Inc | Stock-Other | 1.20% | +0.44% | — | |
| 19 | ARVN | Arvinas Inc | Stock-Other | 1.19% | — | -41.20% | |
| 20 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.15% | -0.23% | +2.04% | |
| 21 | ANNX | Annexon Inc | Stock-Other | 1.12% | -0.81% | — | |
| 22 | GOSS | Gossamer Bio Inc | Stock-Other | 1.01% | — | -23.13% | |
| 23 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.99% | -0.28% | — | |
| 24 | DERM | Journey Medical CORP | Stock-Other | 0.98% | -0.37% | +922.17% | |
| 25 | ✓ | Stock-Other | 0.84% | -1.86% | — | ||
| 26 | PLX | Protalix Biotherapeutics Inc | Stock-Other | 0.81% | -0.10% | EXIT | |
| 27 | TMCI | Treace Medical Concepts Inc | Stock-Other | 0.67% | — | — | |
| 28 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.66% | +0.42% | -4.76% | |
| 29 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 0.65% | — | — | |
| 30 | MBX | Mbx Biosciences Inc | Stock-Other | 0.63% | +0.28% | +5.72% | |
| 31 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.50% | -0.02% | — | |
| 32 | ✓ | Adc Therapeutics SA | Stock-Other | 0.39% | +0.07% | NEW | |
| 33 | ALMS | Alumis Inc | Stock-Other | 0.38% | -0.20% | -14.19% | |
| 34 | CABA | Cabaletta Bio Inc | Stock-Other | 0.27% | +0.60% | — | |
| 35 | IRD | Opus Genetics Inc | Stock-Other | 0.26% | +0.12% | -9.84% | |
| 36 | ZYME | Zymeworks Inc | Stock-Other | 0.24% | — | -52.38% | |
| 37 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.15% | — | — | |
| 38 | RIGL | Rigel Pharmaceuticals Inc | Stock-Other | 0.15% | -0.25% | EXIT | |
| 39 | ACOG | Alpha Cognition Inc | Stock-Other | 0.11% | +0.04% | — | |
| 40 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.07% | +0.18% | -83.55% | |
| 41 | PEPG | Pepgen Inc | Stock-Other | 0.05% | — | -68.75% | |
| 42 | IBIO | Ibio Inc | Stock-Other | 0.04% | — | — | |
| 43 | ADGM | Adagio Medical Holdings Inc | Stock-Other | 0.03% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | HROW | Harrow Inc | +3.2% | — | Trim |
| 2 | STOK | Stoke Therapeutics Inc | +1.8% | +21.33% | Add |
| 3 | CGON | Cg Oncology Inc | +1.4% | +54.14% | Add |
| 4 | LQDA | Liquidia CORP | +1% | +5.66% | Add |
| 5 | RZLT | Rezolute Inc | +0.9% | — | Add |
| 6 | DERM | Journey Medical CORP | +0.9% | +922.17% | Add |
| 7 | IRON | Disc Medicine Inc | +0.9% | +3.95% | Add |
| 8 | RYTM | Rhythm Pharmaceuticals Inc | +0.8% | -2.80% | Trim |
| 9 | LRMR | Larimar Therapeutics Inc | +0.6% | -9.47% | Add |
| 10 | ETON | Eton Pharmaceuticals Inc | +0.6% | — | Add |
| 11 | XOMA | Xoma Royalty Corporation | +0.3% | — | Add |
| 12 | MBX | Mbx Biosciences Inc | +0.2% | +5.72% | Add |
| 13 | OCUL | Ocular Therapeutix Inc | 0% | — | Unchanged |
| 14 | ADGM | Adagio Medical Holdings Inc | 0% | — | Unchanged |
| 15 | GOSS | Gossamer Bio Inc | 0% | -23.13% | Trim |
| 16 | IMNM | Immunome Inc | -0.1% | -9.76% | Trim |
| 17 | IRD | Opus Genetics Inc | -0.1% | -9.84% | Trim |
| 18 | PEPG | Pepgen Inc | -0.1% | -68.75% | Trim |
| 19 | PTGX | Protagonist Therapeutics Inc | -0.1% | — | Unchanged |
| 20 | ZYME | Zymeworks Inc | -0.2% | -52.38% | Trim |
| 21 | IBIO | Ibio Inc | -0.3% | — | Unchanged |
| 22 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | -0.4% | — | Unchanged |
| 23 | TRVI | Trevi Therapeutics Inc | -0.6% | — | Trim |
| 24 | ZNTL | Zentalis Pharmaceuticals Inc | -0.6% | -83.55% | Trim |
| 25 | EWTX | Edgewise Therapeutics Inc | -0.8% | +2.04% | Add |
| 26 | CDXS | Codexis Inc | -1.3% | +1.55% | Add |
| 27 | ARVN | Arvinas Inc | -1.9% | -41.20% | Trim |
| 28 | TGTX | Tg Therapeutics Inc | -2% | — | Unchanged |
| 29 | SNWV | Sanuwave Health Inc | -2.5% | — | Add |
| 30 | APGE | Apogee Therapeutics Inc | — | NEW | New buy |
| 31 | ALKS | Alkermes plc | — | NEW | New buy |
| 32 | SRPT | Sarepta Therapeutics Inc | — | NEW | New buy |
| 33 | ANNX | Annexon Inc | — | NEW | New buy |
| 34 | TARA | Protara Therapeutic Inc | — | EXIT | Sold out |
| 35 | DNA | Ginkgo Bioworks Holdings Inc | — | EXIT | Sold out |
| 36 | GOSS 5 06-01-27Bond | Gossamer Bio Inc | — | EXIT | Sold out |
| 37 | ✓ | — | NEW | New buy | |
| 38 | ANIK | Anika Therapeutics Inc | — | EXIT | Sold out |
| 39 | PLX | Protalix Biotherapeutics Inc | — | NEW | New buy |
| 40 | PVLA | Palvella Therapeutics Inc | — | EXIT | Sold out |
| 41 | TMCI | Treace Medical Concepts Inc | — | NEW | New buy |
| 42 | RVMD | Revolution Medicines Inc | — | NEW | New buy |
| 43 | ANAB | Anaptysbio Inc | — | EXIT | Sold out |
| 44 | ✓ | Acelyrin Inc | — | EXIT | Sold out |
| 45 | RCEL | Avita Medical Inc | — | EXIT | Sold out |
| 46 | EPIEUR | Essa Pharma Inc | — | EXIT | Sold out |
| 47 | ✓ | Adc Therapeutics SA | — | NEW | New buy |
| 48 | CRGX | Cargo Therapeutics Inc | — | EXIT | Sold out |
| 49 | ALMS | Alumis Inc | — | NEW | New buy |
| 50 | ✓ | Biodesix Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Opaleye Management Inc. reported a total U.S. public equity portfolio value of $1.1B across 43 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
APGE
市值: $14.4M
Top Position Liquidated / Trimmed
TARA
前期市值: $7.4M
During Q3 2025, Opaleye Management Inc.'s top holdings by market value included HROW (26.6%)、ETON (8.8%)、LQDA (8.4%). The largest single position, HROW, represented 26.6% of total portfolio value.
In Q3 2025, Opaleye Management Inc. made 53 total portfolio adjustments, initiating 14 new buys, adding to 13 positions, trimming 10 holdings, and fully liquidating 16 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.